Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lucchinetti, C. F.
Right arrow Articles by Lennon, V. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lucchinetti, C. F.
Right arrow Articles by Lennon, V. A.
NEUROLOGY 1998;50:652-657
© 1998 American Academy of Neurology

Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies

Claudia F. Lucchinetti, MD, David W. Kimmel, MD and Vanda A. Lennon, MD, PhD

From the Neuroimmunology Laboratory, Departments of Immunology, Neurology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Address correspondence and reprint request to Dr. Claudia F. Lucchinetti, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Type 1 antineuronal nuclear autoantibody (ANNA-1, also known as "anti-Hu") is a marker of neurologic autoimmunity that is highly associated with small-cell lung carcinoma (SCLC). To determine the spectrum of symptoms and signs as well as the frequency of cancer in adult patients who are seropositive for ANNA-1, we reviewed 162 sequential patients (67% female) identified as ANNA-1-positive in a comprehensive immunofluorescence screening test. In 21% of these patients, the antibody test requested by the physician was not ANNA-1. By the end of the follow-up period, cancer had been found in 142 patients (88%). Ten of these lacked evidence of SCLC (4 had prostate carcinoma, 3 breast carcinoma, 1 both prostate carcinoma and melanoma, 1 lymphoma, and 1 squamous-cell lung carcinoma). Of the 132 patients(81%) with proven SCLC, 17 had one or more coexisting malignant neoplasms (6 had renal carcinoma, 4 another lung primary carcinoma, 3 prostate carcinoma, 3 breast carcinoma, and 4 assorted neoplasms). The diagnosis of SCLC in 128 patients(97%) followed the onset of paraneoplastic symptoms. SCLC was identified in 10 patients by chest MRI after an equivocal chest radiograph or CT; in 28 by bronchoscopy, mediastinoscopy, or thoracotomy; and in 7 at autopsy. Neurologic signs in decreasing frequency were neuropathy (sensory> mixed somatic > autonomic > cranial [especially cranial nerve VIII] > motor), cerebellar ataxia, limbic encephalitis, polyradiculopathy, associated Lambert-Eaton myasthenic syndrome, myopathy, myelopathy, opsoclonus/myoclonus, motor neuronopathy, brachial plexopathy, and aphasia. Nineteen patients had a solely gastrointestinal initial presentation, including gastroparesis, pseudo-obstruction, esophageal achalasia, or other dysmotility. We conclude that seropositivity for ANNA-1 can expedite the diagnosis and treatment of otherwise occult cancer in patients, especially tobacco abusers, with varied neurologic and gastroenterologic presentations. The search for SCLC should not end on discovering a different neoplasm.


Supported by grant CA-37343 from the National Cancer Institute.

Received November 15, 1996. Accepted in final form June 19, 1997.




This article has been cited by other articles:


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J Honnorat, S Cartalat-Carel, D Ricard, J P. Camdessanche, A F Carpentier, V Rogemond, F Chapuis, M Aguera, E Decullier, A M Duchemin, et al.
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies
J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 412 - 416.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
A Saiz, J Bruna, P Stourac, M C Vigliani, B Giometto, W Grisold, J Honnorat, D Psimaras, R Voltz, and F Graus
Anti-Hu-associated brainstem encephalitis
J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 404 - 407.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. Vincent, C. Buckley, B. Lang, S. Irani, S. J. Pittock, and K. Meng Tan
CLINICAL SPECTRUM OF VOLTAGE-GATED POTASSIUM CHANNEL AUTOIMMUNITY
Neurology, January 6, 2009; 72(1): 99 - 100.
[Full Text] [PDF]


Home page
NEJMHome page
K. R. Daffner, J. C. Sherman, R. G. Gonzalez, and R. P. Hasserjian
Case 35-2008 -- A 65-Year-Old Man with Confusion and Memory Loss
N. Engl. J. Med., November 13, 2008; 359(20): 2155 - 2164.
[Full Text] [PDF]


Home page
NeurologyHome page
K. M. Tan, V. A. Lennon, C. J. Klein, B. F. Boeve, and S. J. Pittock
Clinical spectrum of voltage-gated potassium channel autoimmunity
Neurology, May 13, 2008; 70(20): 1883 - 1890.
[Abstract] [Full Text] [PDF]


Home page
PNHome page
U. Schulz, B. Randalls, and C. Counsell
Anti-Hu syndrome: a rare presentation and a very difficult decision
Practical Neurology, October 1, 2007; 7(5): 336 - 341.
[Full Text] [PDF]


Home page
The OncologistHome page
J. W. de Beukelaar and P. A. S. Smitt
Managing paraneoplastic neurological disorders.
Oncologist, March 1, 2006; 11(3): 292 - 305.
[Abstract] [Full Text] [PDF]


Home page
Nutr Clin PractHome page
D. H. Sutton, S. P. Harrell, and J. M. Wo
Diagnosis and Management of Adult Patients With Chronic Intestinal Pseudoobstruction
Nutr Clin Pract, February 1, 2006; 21(1): 16 - 22.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. Martinu and A. S. Clay
A 50-Year-Old Woman With Bilateral Vocal Cord Paralysis and Hilar Mass
Chest, August 1, 2005; 128(2): 1028 - 1031.
[Full Text] [PDF]


Home page
Diabetes CareHome page
A. I. Vinik, D. Anandacoomaraswamy, and J. Ullal
Antibodies to Neuronal Structures: Innocent bystanders or neurotoxins?
Diabetes Care, August 1, 2005; 28(8): 2067 - 2072.
[Full Text] [PDF]


Home page
NeurologyHome page
N. G. Muller, K. Prass, and R. Zschenderlein
Anti-Hu antibodies, sensory neuropathy, and Holmes-Adie syndrome in a patient with seminoma
Neurology, January 11, 2005; 64(1): 164 - 165.
[Full Text] [PDF]


Home page
NeurologyHome page
A. Llado, P. Mannucci, A. F. Carpentier, S. Paris, Y. Blanco, A. Saiz, J. Y. Delattre, and F. Graus
Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes
Neurology, November 23, 2004; 63(10): 1947 - 1949.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. Sinnreich, C. J. Klein, J. R. Daube, J. Engelstad, R. J. Spinner, and P. J.B. Dyck
Chronic immune sensory polyradiculopathy: A possibly treatable sensory ataxia
Neurology, November 9, 2004; 63(9): 1662 - 1669.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Vernino and V. A. Lennon
Autoantibody Profiles and Neurological Correlations of Thymoma
Clin. Cancer Res., November 1, 2004; 10(21): 7270 - 7275.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
S. Younes-Mhenni, M. F. Janier, L. Cinotti, J. C. Antoine, F. Tronc, V. Cottin, P. J. Ternamian, P. Trouillas, and J. Honnorat
FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes
Brain, October 1, 2004; 127(10): 2331 - 2338.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
R. Linke, M. Schroeder, T. Helmberger, and R. Voltz
Antibody-positive paraneoplastic neurologic syndromes: Value of CT and PET for tumor diagnosis
Neurology, July 27, 2004; 63(2): 282 - 286.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
N. D. Lawn, B. F. Westmoreland, M. J. Kiely, V. A. Lennon, and S. Vernino
Clinical, Magnetic Resonance Imaging, and Electroencephalographic Findings in Paraneoplastic Limbic Encephalitis
Mayo Clin. Proc., November 1, 2003; 78(11): 1363 - 1368.
[Abstract] [PDF]


Home page
NeurologyHome page
S. Vernino, E. R. Eggenberger, L. R. Rogers, and V. A. Lennon
Paraneoplastic neurological autoimmunity associated with ANNA-1 autoantibody and thymoma
Neurology, September 24, 2002; 59(6): 929 - 932.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
M. P. Buetow and E. Eggenberger
ANNA-1--Induced Encephalitis Associated with Noninvasive Thymoma
Am. J. Roentgenol., September 1, 2002; 179(3): 802 - 803.
[Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
P N Shams, A Waldman, and G T Plant
B Cell lymphoma of the brain stem masquerading as myasthenia
J. Neurol. Neurosurg. Psychiatry, February 1, 2002; 72(2): 271 - 273.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
J.-P. Camdessanche, J.-C. Antoine, J. Honnorat, C. Vial, P. Petiot, P. Convers, and D. Michel
Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: A clinical and electrophysiological study of 20 patients
Brain, January 1, 2002; 125(1): 166 - 175.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. A. Amato and M. P. Anderson
Case 38-2001- A 51-Year-Old Woman with Lung Cancer and Neuropsychiatric Abnormalities
N. Engl. J. Med., December 13, 2001; 345(24): 1758 - 1765.
[Full Text] [PDF]


Home page
BrainHome page
J. H. Rees, S. F. Hain, M. R. Johnson, R. A. C. Hughes, D. C. Costa, P. J. Ell, G. Keir, and P. Rudge
The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders
Brain, November 1, 2001; 124(11): 2223 - 2231.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Brichory, D. Beer, F. LeNaour, T. Giordano, and S. Hanash
Proteomics-based Identification of Protein Gene Product 9.5 as a Tumor Antigen That Induces a Humoral Immune Response in Lung Cancer
Cancer Res., November 1, 2001; 61(21): 7908 - 7912.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
F. Graus, F. Keime-Guibert, R. Rene, B. Benyahia, T. Ribalta, C. Ascaso, G. Escaramis, and J. Y. Delattre
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Brain, June 1, 2001; 124(6): 1138 - 1148.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
M Abu-Shakra, D Buskila, M Ehrenfeld, K Conrad, and Y Shoenfeld
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies
Ann Rheum Dis, May 1, 2001; 60(5): 433 - 441.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M Barnett, J Prosser, I Sutton, G M Halmagyi, L Davies, C Harper, and J Dalmau
Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody
J. Neurol. Neurosurg. Psychiatry, February 1, 2001; 70(2): 222 - 225.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. Vernino, P. A. Low, R. D. Fealey, J. D. Stewart, G. Farrugia, and V. A. Lennon
Autoantibodies to Ganglionic Acetylcholine Receptors in Autoimmune Autonomic Neuropathies
N. Engl. J. Med., September 21, 2000; 343(12): 847 - 855.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
S. H. Gultekin, M. R. Rosenfeld, R. Voltz, J. Eichen, J. B. Posner, and J. Dalmau
Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients
Brain, July 1, 2000; 123(7): 1481 - 1494.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
P. H. King
RNA-binding analyses of HuC and HuD with the VEGF and c-myc 3'-untranslated regions using a novel ELISA-based assay
Nucleic Acids Res., April 1, 2000; 28(7): e20 - e20.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
F. Keime-Guibert, F. Graus, P. Broet, R. Rene, J. L. Molinuevo, C. Ascaso, and J. Y. Delattre
Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor
Neurology, November 1, 1999; 53(8): 1719 - 1719.
[Abstract] [Full Text]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J.-C. Antoine, J.-F. Mosnier, L. Absi, P. Convers, J. Honnorat, and D. Michel
Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies
J. Neurol. Neurosurg. Psychiatry, July 1, 1999; 67(1): 7 - 14.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.